Shackelford Pharma Inc.

[On Demand]

In February 2021 Jazz Pharmaceuticals entered into an agreement to purchase GW Pharma for $7.2B. This acquisition highlighted the rapidly emerging field of endocannabinoid therapeutics.

By Q1 2022 Shackelford Pharma Inc. (SPI) aims to have 3 drug candidates for neurological conditions entering clinical trials.

Dr. Alan Shackelford has worked with over 25,000 patients and has treated over 30 different disorders with his endocannabinoid-based therapies. Over 20 of those are considered rare and orphan.

An experienced management team is utilizing the real-world evidence in his patient database to identify, develop and commercialize the best candidates for drug development. SPI screened the database based not only on real world results but also on consideration of strategic clinical development, regulatory and commercial factors. As a result, we believe that we have significantly de-risked Shackelford Pharma’s drug development programs.

Company Type:
Privately Funded Company
Company HQ State:
British Columbia
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Mild Cognitive Impairment/Early Alzheimer's Disease
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Founder, Chief Executive Officer & Director
Shackelford Pharma Inc.